Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Change in Cash (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Change in Cash for 4 consecutive years, with $6.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Cash rose 15450.34% to $6.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.9 million, a 284.21% increase, with the full-year FY2024 number at -$1.7 million, up 80.03% from a year prior.
  • Change in Cash was $6.9 million for Q3 2025 at bioAffinity Technologies, up from $358129.0 in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $13.3 million in Q3 2022 to a low of -$3.8 million in Q3 2023.
  • A 4-year average of $420570.5 and a median of -$660585.0 in 2025 define the central range for Change in Cash.
  • Peak YoY movement for Change in Cash: plummeted 394.48% in 2023, then soared 15450.34% in 2025.
  • bioAffinity Technologies' Change in Cash stood at -$2.1 million in 2022, then grew by 19.02% to -$1.7 million in 2023, then skyrocketed by 120.66% to $348711.0 in 2024, then soared by 1869.07% to $6.9 million in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Change in Cash are $6.9 million (Q3 2025), $358129.0 (Q2 2025), and -$660585.0 (Q1 2025).